NCT04184882 - A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

September 4, 2022

Study Completion Date

September 4, 2022

Conditions

Duchenne Muscular Dystrophy (DMD)

Interventions

DRUG

Bocidelpar

Oral

DRUG

Placebo

Oral

Trial Locations (5)

Kennedy Krieger Institute, Baltimore

Children's Hospital of Richmond at VCU, Richmond

University of Kansas Medical Center, Kansas City

University of California Davis Health, Sacramento

UMass Memorial Medical Center, Worcester